SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte’s Chief Operating Officer (Heather Prichard) detailing problems with Humacyte’s facilities. The FDA’s April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earnings call on May 12, 2024 in response to analyst questions.
Hagens Berman urges investors in Humacyte, Inc. (NASDAQ: HUMA) who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/huma
Contact the Firm Now: HUMA@hbsslaw.com
844-916-0895
Investigation Into Humacyte, Inc. (HUMA):
The investigation focuses on Humacyte’s statements about the FDA’s inspections and the company’s disclosures about its communications with the FDA’s inspections, particularly about the FDA’s inspections of the company’s facilities for the manufacture of its tissue engineered vessel (ATEV) in the vascular trauma indication.
On May 12, 2024, during the company’s Q1 2024 earnings call, an analyst specifically questioned Humacyte management about the company’s facility inspection with the FDA. Humacyte’s Chief Operating Officer (Heather Prichard) said in part that “our manufacturing facility and had a very successful outcome[] [a]nd based on the outcome of inspection and all of the other FDA interactions on the whole, we remain very confident in approval of HAV in vascular trauma.”
When Prichard made the above statements, the FDA had on April 5, 2024 sent her a letter on Form 483 which was not published until October 17, 2024 that communicated serious matters listing inspectional observations. The FDA observed in its April 5, 2024 Form 483 that the company’s facility had no microbial quality assurance, inadequate quality assurance, and reciting that under FDA regulations its observer in his or her judgment indicated that the observations consisted in whole or part of filthy, putrid, or decomposed substance or has been prepared, packed or held under insanitary conditions whereby it may have been become contaminated with filth, or whereby it may have been rendered injurious to health.
But on August 12, 2024, Humacyte’s shares plunged 16% on news that the FDA communicated its delay in considering the company’s biologics license application for ATEV. Then, on October 17, 2024 the FDA published its April 5, 2024 Form 483 addressed to Prichard, driving the price of Humacyte shares down another 16%.
“We’re focused on Prichard’s ‘very successful outcome’ assurance versus the FDA’s publication on October 17, 2024,” said Reid Kathrein, the partner leading the investigation.
If you invested in Humacyte or have knowledge that may assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to frequently asked questions about the Humacyte investigation, read more »
Whistleblowers: Persons with non-public information regarding Humacyte should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email HUMA@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
